Related Experiment Video
Updated: May 28, 2026
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Development of an Active Chimeric IL13Rα2 ADC for Diffuse Intrinsic Pontine Glioma.
Xiaolei Lian1,2,3, Victoria J Allanson2, Samuel V Rasmussen2
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Immunotargets and Therapy
|May 27, 2026
Summary
A new antibody-drug conjugate (ADC) targeting IL13Rα2 shows promise for treating diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain cancer. This preclinical therapy demonstrated significant tumor reduction in both ex ovo and in vivo models.
Area of Science:
- Oncology
- Pediatric Neuro-oncology
- Drug Development
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a rare pediatric brain tumor with limited treatment options.
- Surgical removal is impossible, and radiation offers only temporary relief.
- Recent FDA approvals suggest DIPG therapy is achievable.
Purpose of the Study:
- To develop a novel therapeutic agent for DIPG.
- To target IL13Rα2, which is overexpressed in DIPG tumors.
- To create a deruxtecan-conjugated antibody-drug conjugate (ADC).
Main Methods:
- Identified IL13Rα2 overexpression in DIPG tissues.
- Developed a chimeric antibody targeting IL13Rα2.
- Conjugated the antibody with deruxtecan to form an ADC.
- Validated the ADC in vitro and in quail and mouse xenograft models.
Main Results:
- The ADC demonstrated dose-dependent and IL13Rα2-dependent cell death in vitro.
- Tumor reduction was observed in ex ovo quail embryo models (IL13Rα2-high and low).
- In vivo mouse xenografts showed reduced tumor volume compared to antibody treatment alone.
Conclusions:
- This study presents a significant preclinical advancement for a novel deruxtecan-based ADC targeting DIPG.
- The findings support the potential of ADCs in treating intractable pediatric brain cancers.
- This work aligns with the growing clinical success of ADC agents in various indications.
